最高法院介入：特朗普紧急关税措施被否决
Supreme Court steps in: Trump's emergency tariffs struck down
生命科学资讯
生物技术与制药领域的最新动态
Ionis终止针对唐氏综合征患者阿尔茨海默病的早期候选药物研发。
Ionis scraps early candidate for Alzheimer’s in people with Down syndrome
Ionis终止针对唐氏综合症患者的阿尔茨海默病药物研发。
Ionis scraps Alzheimer’s drug for people with Down syndrome
最高法院裁定特朗普基于紧急权力的关税无效
Supreme Court invalidates Trump tariffs based on emergency powers
最高法院关税裁决维持特朗普针对制药业的权力
Supreme Court tariff ruling lets stand Trump’s authority to target pharma
罗氏获FDA乳腺癌新药审批日期，备受关注。
Roche gets FDA decision date on closely watched breast cancer drug
圣地亚哥新秀公司以100美元基因组测序震撼Illumina市场
San Diego Upstart Drops $100 Genome Bombshell on Illumina - Hoodline
华尔街分析师对沃特世公司股票的目标价是多少？ - Barchart.com
What Are Wall Street Analysts' Target Price for Waters Corporation Stock? - Barchart.com
生物制药融资情况：2026年1月1日至2月19日
Biopharma money raised: Jan. 1-Feb. 19, 2026
生物制药筹集的资金
Money raised by biopharma
10x Genomics获瑞银上调目标价至20美元 | TXG股票动态 - GuruFocus
TXG: UBS Raises Price Target for 10x Genomics to $20 | TXG Stock News - GuruFocus
溶酶体KICSTOR-GATOR1-SAMTOR营养感知超级复合物的结构
Structure of the lysosomal KICSTOR-GATOR1-SAMTOR nutrient-sensing supercomplex
生态困境中的共生固守
Symbiotic entrenchment through ecological Catch-22
Grail股价暴跌，因NHS-Galleri癌症血液检测关键试验未达主要终点。
Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint
Mainz Biomed计划剥离ColoAlert业务，调整美国市场战略重心。
Mainz Biomed looks to shed ColoAlert, shifts focus in US
罗氏任命澳大利亚肿瘤学家领导早期研究——机遇与挑战并存
Chutes & Ladders—Roche taps Aussie oncologist to lead early research
Biohaven在FDA打击后规划回归之路，押注肥胖症市场。
Biohaven charts comeback path after FDA blow, placing bets on obesity
Madrigal股价遭遇抛售；前诺华高管转投第一三共。
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
Cytiva如何借助Veeva RIM统一医疗器械与生物技术监管体系——Veeva
How Cytiva Unified MedTech and BioTech Regulatory Divisions with Veeva RIM - Veeva
最高法院裁定特朗普关税政策无效
Supreme Court rules against Trump tariffs